Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Main Capital and Aunetic in connection with the acquisition of Qnister
Mandate

Vinge advises Main Capital and Aunetic in connection with the acquisition of Qnister

October 25, 2024 Employment and Benefits M&A Data protection and processing of personal data Intellectual Property Commercial Agreements

Vinge has advised Aunetic, a leading governance software specialist, in connection with the acquisition of Qnister AB (“Qnister”). The strategic acquisition enhances Aunetic’s product portfolio and strengthens its presence in the Swedish software compliance market.

Founded in 2017, Qnister is as a SaaS-company specialising in compliance software solutions, providing GDPR and whistleblowing solutions as well as services in sanctions screening and contract management to small and medium-sized enterprises in the private sector and to customers within the public sector.

The acquisition aligns with Aunetic’s goal to expand its compliance software suite and market reach, positioning Aunetic as a leading governance software group in Europe.

Vinge’s team mainly consisted of Filip Öhrner, Linus Adolfsson, Jonatan Stentorp (M&A), Emil Lindwall, Gulestan Ali (Employment), Carla Håkansson (Commercial Agreements & GDPR), Ian Jonson (IP) and Gabriella Balbo (Transaction Support Coordinator).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026